An unexpected ally in heart failure treatment: Unlocking the potential of sodium-glucose cotransporter 2 inhibitors across patient subpopulations.
作者信息
Trenson Sander, Sokolski Mateusz
机构信息
Department of Cardiology, Sint-Jan Hospital Bruges, Bruges, Belgium.
Faculty of Medicine, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
出版信息
ESC Heart Fail. 2025 Jun;12(3):1532-1534. doi: 10.1002/ehf2.15167. Epub 2024 Nov 16.
Abstract
摘要
相似文献
1
An unexpected ally in heart failure treatment: Unlocking the potential of sodium-glucose cotransporter 2 inhibitors across patient subpopulations.
ESC Heart Fail. 2025 Jun;12(3):1532-1534. doi: 10.1002/ehf2.15167. Epub 2024 Nov 16.
2
Potential of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Heart Failure With Preserved Ejection Fraction: A Narrative Review.
Cureus. 2024 Nov 18;16(11):e73906. doi: 10.7759/cureus.73906. eCollection 2024 Nov.
3
Sodium-glucose cotransporter-2 inhibitor use in patients with a Fontan circulation.
Cardiol Young. 2025 Apr;35(4):745-747. doi: 10.1017/S1047951125000514. Epub 2025 Feb 26.
4
Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature.
Heart Fail Rev. 2024 Mar;29(2):549-558. doi: 10.1007/s10741-024-10388-9. Epub 2024 Feb 1.
5
Effects of sodium-glucose cotransporter-2 inhibitors on nutritional status in heart failure with reduced ejection fraction.
Rev Assoc Med Bras (1992). 2022 Nov 28;68(11):1576-1581. doi: 10.1590/1806-9282.20220737. eCollection 2022.
6
Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy.
Basic Clin Pharmacol Toxicol. 2022 Apr;130(4):425-438. doi: 10.1111/bcpt.13714. Epub 2022 Feb 17.
7
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
Circulation. 2019 Nov 5;140(19):1569-1577. doi: 10.1161/CIRCULATIONAHA.119.042685. Epub 2019 Aug 31.
8
Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update.
Pharmaceuticals (Basel). 2024 Oct 23;17(11):1419. doi: 10.3390/ph17111419.
9
Heterogeneity in cardiorenal protection by Sodium glucose cotransporter 2 inhibitors in heart failure across the ejection fraction strata: Systematic review and meta-analysis.
World J Nephrol. 2023 Dec 25;12(5):182-200. doi: 10.5527/wjn.v12.i5.182.
10
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Adv Ther. 2022 Feb;39(2):845-861. doi: 10.1007/s12325-021-01989-z. Epub 2021 Dec 9.
本文引用的文献
1
Safety of sodium-glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and meta-analysis.
ESC Heart Fail. 2024 Apr;11(2):637-648. doi: 10.1002/ehf2.14633. Epub 2023 Dec 20.
2
Sodium-glucose cotransporter 2 inhibitors are associated with reduced risk of mortality and readmissions in heart failure.
ESC Heart Fail. 2024 Feb;11(1):327-337. doi: 10.1002/ehf2.14582. Epub 2023 Nov 27.
3
Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.
ESC Heart Fail. 2024 Feb;11(1):261-270. doi: 10.1002/ehf2.14565. Epub 2023 Nov 15.
4
Dapagliflozin treatment and cardiovascular outcome in RBP4/TTR (transthyretin cardiac amyloidosis) mice.
ESC Heart Fail. 2024 Feb;11(1):179-188. doi: 10.1002/ehf2.14567. Epub 2023 Oct 25.
5
Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40.
ESC Heart Fail. 2023 Dec;10(6):3385-3397. doi: 10.1002/ehf2.14470. Epub 2023 Sep 5.
6
Cost-utility analysis of add-on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction.
ESC Heart Fail. 2023 Aug;10(4):2524-2533. doi: 10.1002/ehf2.14426. Epub 2023 Jun 8.
7
Neurohormonal blockade in transthyretin amyloidosis: perhaps one size does not fit all?
Eur Heart J. 2023 Aug 14;44(31):2908-2910. doi: 10.1093/eurheartj/ehad357.
8
Conventional heart failure therapy in cardiac ATTR amyloidosis.
Eur Heart J. 2023 Aug 14;44(31):2893-2907. doi: 10.1093/eurheartj/ehad347.
9
Cardio-renal-metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort.
ESC Heart Fail. 2023 Aug;10(4):2269-2280. doi: 10.1002/ehf2.14381. Epub 2023 Apr 24.
10
Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction.
ESC Heart Fail. 2023 Jun;10(3):2010-2018. doi: 10.1002/ehf2.14347. Epub 2023 Apr 11.
Zotero 插件